MA51530B1 - Composés cycliques fondus - Google Patents
Composés cycliques fondusInfo
- Publication number
- MA51530B1 MA51530B1 MA51530A MA51530A MA51530B1 MA 51530 B1 MA51530 B1 MA 51530B1 MA 51530 A MA51530 A MA 51530A MA 51530 A MA51530 A MA 51530A MA 51530 B1 MA51530 B1 MA 51530B1
- Authority
- MA
- Morocco
- Prior art keywords
- fused ring
- ring compounds
- compounds
- inhibition
- administration
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 150000001923 cyclic compounds Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000016914 ras Proteins Human genes 0.000 abstract 1
- 108010014186 ras Proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
L'invention concerne des composés cycliques fondus de formule (I), tels que décrits dans la description, qui sont utilisés pour l'inhibition de protéines Ras, ainsi que des compositions comprenant ces composés et des méthodes de traitement impliquant leur administration.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018114788 | 2018-11-09 | ||
| PCT/US2019/060578 WO2020097537A2 (fr) | 2018-11-09 | 2019-11-08 | Composés cycliques fondus |
| EP19842848.4A EP3735299B1 (fr) | 2018-11-09 | 2019-11-08 | Composés cycliques fondus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA51530A MA51530A (fr) | 2021-04-21 |
| MA51530B1 true MA51530B1 (fr) | 2024-12-31 |
Family
ID=69232886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51530A MA51530B1 (fr) | 2018-11-09 | 2019-11-08 | Composés cycliques fondus |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US11236068B2 (fr) |
| EP (2) | EP4483881A3 (fr) |
| JP (4) | JP6941241B2 (fr) |
| KR (3) | KR102587544B1 (fr) |
| CN (5) | CN118084867A (fr) |
| AR (1) | AR117194A1 (fr) |
| AU (3) | AU2019377130B2 (fr) |
| BR (1) | BR112021008986A2 (fr) |
| CA (1) | CA3087089C (fr) |
| CL (2) | CL2021001171A1 (fr) |
| CO (1) | CO2021005987A2 (fr) |
| CR (1) | CR20210229A (fr) |
| DK (1) | DK3735299T3 (fr) |
| ES (1) | ES3004042T3 (fr) |
| FI (1) | FI3735299T3 (fr) |
| HR (1) | HRP20241581T1 (fr) |
| HU (1) | HUE069365T2 (fr) |
| IL (3) | IL311187B2 (fr) |
| LT (1) | LT3735299T (fr) |
| MA (1) | MA51530B1 (fr) |
| MX (5) | MX2021005428A (fr) |
| MY (1) | MY196726A (fr) |
| PE (2) | PE20260440A1 (fr) |
| PH (1) | PH12021551065A1 (fr) |
| PL (1) | PL3735299T3 (fr) |
| PT (1) | PT3735299T (fr) |
| RS (1) | RS66280B1 (fr) |
| SG (1) | SG11202103298QA (fr) |
| SI (1) | SI3735299T1 (fr) |
| SM (1) | SMT202400487T1 (fr) |
| TW (2) | TWI883352B (fr) |
| UA (1) | UA127930C2 (fr) |
| WO (1) | WO2020097537A2 (fr) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119569702A (zh) | 2018-04-04 | 2025-03-07 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| TWI831855B (zh) | 2018-10-26 | 2024-02-11 | 日商大鵬藥品工業股份有限公司 | 新穎吲唑化合物或其鹽 |
| CN114437065A (zh) | 2019-05-21 | 2022-05-06 | 益方生物科技(上海)股份有限公司 | 杂环化合物，其制备方法和用途 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CA3158793A1 (fr) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Inhibiteurs a petites molecules de mutant de kras g12c |
| EP4065231A1 (fr) * | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
| WO2021106230A1 (fr) | 2019-11-29 | 2021-06-03 | 大鵬薬品工業株式会社 | Nouveau composé phénolique ou sel de celui-ci |
| WO2021120045A1 (fr) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Composés hétérocycliques, leurs procédés de préparation et utilisations associées |
| WO2021138391A1 (fr) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Composés d'indazole |
| KR20230042600A (ko) | 2020-06-18 | 2023-03-28 | 레볼루션 메디슨즈, 인크. | Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법 |
| BR112023002591A2 (pt) * | 2020-08-12 | 2023-04-04 | Genentech Inc | Processo para a preparação de um composto e composto |
| JP2023538060A (ja) * | 2020-08-17 | 2023-09-06 | 貝達薬業股▲ふん▼有限公司 | 二環化合物、それを含む組成物、及びそれらの使用 |
| EP4203952A4 (fr) | 2020-08-28 | 2024-12-11 | Kumquat Biosciences Inc. | Composés hétérocycliques et leurs utilisations |
| CA3187757A1 (fr) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Utilisation d'inhibiteurs de sos1 pour traiter des malignites a mutations de shp2 |
| US12286431B2 (en) | 2020-09-11 | 2025-04-29 | Mirati Therapeutics, Inc. | Crystalline forms of a KRas G12C inhibitor |
| MX2023003338A (es) | 2020-09-23 | 2023-06-14 | Erasca Inc | Piridonas y pirimidonas tricíclicas. |
| US20230365563A1 (en) * | 2020-09-30 | 2023-11-16 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinazoline compound and application thereof |
| US20240034733A1 (en) * | 2020-11-03 | 2024-02-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| CN116568326A (zh) * | 2020-11-13 | 2023-08-08 | 基因泰克公司 | 用于治疗实体瘤的方法及包括krasg12c抑制剂和vegf抑制剂的组合物 |
| US12171763B2 (en) * | 2020-11-13 | 2024-12-24 | Genentech, Inc. | Methods and compositions comprising a KRASG12C inhibitor and a PD-L1 binding antagonist for treating lung cancer |
| WO2022105855A1 (fr) * | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Inhibiteurs de kras g12d |
| US20240025918A1 (en) * | 2020-11-20 | 2024-01-25 | Jacobio Pharmaceuticals Co., Ltd | KRAS G12D Inhibitors |
| AU2021397214B2 (en) * | 2020-12-08 | 2025-01-23 | Genentech, Inc. | Methods and compositions comprising a krasg12c inhibitor and a egfr-inhibitor for treating solid tumors |
| US12398154B2 (en) | 2020-12-15 | 2025-08-26 | Mirati Therapeutics, Inc. | Azaquinazoline pan-KRas inhibitors |
| EP4262803A4 (fr) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Inhibiteurs pan-kras de tétrahydropyridopyrimidine |
| AU2021407653B9 (en) * | 2020-12-22 | 2025-06-05 | Shanghai Kechow Pharma, Inc | Preparation and application method of heterocyclic compound as kras inhibitor |
| CN113999226B (zh) * | 2020-12-22 | 2023-01-06 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| CN114685532A (zh) * | 2020-12-31 | 2022-07-01 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
| WO2022171018A1 (fr) * | 2021-02-09 | 2022-08-18 | 苏州泽璟生物制药股份有限公司 | Inhibiteur d'amine de benzopyrimidine ou de pyridopyrimidine substitué, son procédé de préparation et son utilisation |
| WO2022171013A1 (fr) * | 2021-02-09 | 2022-08-18 | 南京明德新药研发有限公司 | Composé de tétrahydroquinazoline |
| CN116867792A (zh) * | 2021-02-09 | 2023-10-10 | 基因泰克公司 | 四环氧氮杂䓬化合物及其用途 |
| JP2024506329A (ja) * | 2021-02-09 | 2024-02-13 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環式化合物およびその使用 |
| JP2024508755A (ja) * | 2021-02-16 | 2024-02-28 | セラス， インコーポレイテッド | Ｋｒａｓを阻害するための組成物及び方法 |
| CN117715915A (zh) * | 2021-04-09 | 2024-03-15 | 杭州英创医药科技有限公司 | 作为kras g12d抑制剂的杂环化合物 |
| WO2022221386A1 (fr) * | 2021-04-14 | 2022-10-20 | Erasca, Inc. | Inhibiteurs sélectifs de kras |
| EP4322954A4 (fr) * | 2021-04-16 | 2025-01-29 | Merck Sharp & Dohme LLC | Inhibiteurs à petites molécules de mutant de kras g12d |
| US20250059205A1 (en) * | 2021-04-29 | 2025-02-20 | Amgen Inc. | Heterocyclic Compounds and Methods of Use |
| EP4334324A1 (fr) * | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
| EP4340883A1 (fr) * | 2021-05-19 | 2024-03-27 | Genentech, Inc. | Polythérapie |
| WO2022247760A1 (fr) * | 2021-05-22 | 2022-12-01 | 上海科州药物研发有限公司 | Composés hétérocycliques utiles en tant qu'inhibiteurs de kras, leur préparation et leur utilisation thérapeutique |
| WO2022251496A1 (fr) * | 2021-05-26 | 2022-12-01 | Cornell University | Macrocycles rigidifiés, complexes comportant des radionucléides et utilisation en radiothérapie ciblée du cancer |
| IL310291A (en) | 2021-07-23 | 2024-03-01 | Theras Inc | Compositions and methods for inhibition of ras |
| CN117858878A (zh) * | 2021-08-18 | 2024-04-09 | 北京加科思新药研发有限公司 | N-环丙基吡啶并[4,3-d]嘧啶-4-胺衍生物及其用途 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| EP4395769A1 (fr) | 2021-09-01 | 2024-07-10 | Novartis AG | Combinaisons pharmaceutiques comprenant un inhibiteur de tead et leurs utilisations pour le traitement de cancers |
| EP4436957A1 (fr) | 2021-11-24 | 2024-10-02 | Genentech, Inc. | Composés d'indazole thérapeutiques et méthodes d'utilisation dans le traitement du cancer |
| EP4436969A2 (fr) | 2021-11-24 | 2024-10-02 | Genentech, Inc. | Composés thérapeutiques et méthodes d'utilisation |
| JP2024543879A (ja) * | 2021-11-24 | 2024-11-26 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｋｒａｓ変異型タンパク質の小分子阻害剤 |
| AU2022421224A1 (en) | 2021-12-22 | 2024-06-20 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| US20250188085A1 (en) * | 2022-01-06 | 2025-06-12 | Theras, Inc. | Compositions and methods for inhibition of ras |
| US20250084079A1 (en) * | 2022-01-06 | 2025-03-13 | Theras, Inc. | Compositions and methods for inhibition of ras |
| AU2023215488B2 (en) * | 2022-02-07 | 2026-05-07 | Genentech, Inc. | Solid forms of 1-((s)-4-((r)-7-(6-amino-4-methyl-3- (trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((s)-1- methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3- methylpiperazin-1-yl)prop-2-en-1-one |
| WO2023150653A1 (fr) | 2022-02-07 | 2023-08-10 | Genentech, Inc. | Procédé de synthèse de composés de quinazoline |
| EP4489738A4 (fr) | 2022-03-11 | 2026-03-18 | Kumquat Biosciences Inc | Composés hétérocycliques et leurs utilisations |
| WO2023190748A1 (fr) | 2022-03-31 | 2023-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Composition pharmaceutique pour le traitement de tumeurs |
| CN119013026A (zh) | 2022-04-06 | 2024-11-22 | 基因泰克公司 | 用于治疗癌症的包含gdc-6036和gdc-0077的组合疗法 |
| CR20240508A (es) | 2022-05-19 | 2024-12-20 | Genentech Inc | Compuestos aza-tetracíclicos de oxazepina y usos de los mismos |
| CN115043729B (zh) * | 2022-07-04 | 2024-09-27 | 青岛大学 | 一种2,2’-二氟联芳基化合物的不对称合成方法 |
| KR20250060956A (ko) | 2022-08-05 | 2025-05-07 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| WO2024036270A1 (fr) | 2022-08-11 | 2024-02-15 | Bristol-Myers Squibb Company | Inhibiteurs de kras |
| JP2025528836A (ja) | 2022-08-17 | 2025-09-02 | ツリーライン バイオサイエンシズ インコーポレイテッド | ピリドピリミジンＫＲａｓ阻害剤 |
| WO2024081674A1 (fr) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Polythérapies pour le traitement du cancer |
| JP2025541682A (ja) | 2022-11-21 | 2025-12-23 | ツリーライン バイオサイエンシズ インコーポレイテッド | スピロ環式ジヒドロピランピリミジンＫＲａｓ阻害剤 |
| CN115920658B (zh) * | 2023-01-15 | 2023-10-20 | 安徽科博瑞环境科技有限公司 | 低表面能抗污染中空纤维膜及其制备方法 |
| WO2024153119A1 (fr) * | 2023-01-18 | 2024-07-25 | Suzhou Zanrong Pharma Limited | Inhibiteurs de kras g12d et leurs utilisations |
| WO2024158778A1 (fr) * | 2023-01-24 | 2024-08-02 | Theras, Inc. | Compositions et procédés d'inhibition de ras |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN120813358A (zh) | 2023-04-06 | 2025-10-17 | 卫材R&D管理有限公司 | 用于治疗肿瘤的药物组合物 |
| CN116396202A (zh) * | 2023-04-17 | 2023-07-07 | 南京优氟医药科技有限公司 | 一种（2s，4s）-4-氟代吡咯烷-2-羧酸的制备方法 |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| AU2024285370A1 (en) | 2023-06-06 | 2026-01-08 | Kumquat Biosciences Inc. | Substituted heterocycles and uses thereof |
| US20250000802A1 (en) | 2023-06-09 | 2025-01-02 | Hoffmann-La Roche Inc. | Solid formulations comprising an inhibitor of the k-ras protein having a g12c mutation, and a process for preparing |
| WO2025010415A1 (fr) * | 2023-07-05 | 2025-01-09 | The Regents Of The University Of California | Inhibiteurs de gtpase et leurs utilisations |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024344161A1 (en) | 2023-09-21 | 2026-03-26 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyridine kras inhibitors |
| IL327380A (en) | 2023-09-29 | 2026-05-01 | D3 Bio Wuxi Co Ltd | Combinations of WX-001 or its derivatives with KRAS G12C inhibitor for use in cancer treatment |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025085748A1 (fr) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Inhibiteurs à petites molécules de protéines kras |
| WO2025171296A1 (fr) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2025240847A1 (fr) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2025245127A1 (fr) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Inhibiteurs de dihydropyranopyrimidine kras spirocycliques |
| WO2025255438A1 (fr) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras |
| WO2025265060A1 (fr) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Compositions thérapeutiques et procédés de gestion d'effets liés au traitement |
| WO2026006747A1 (fr) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026015796A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015801A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble liés à ras |
| WO2026015825A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas |
| WO2026015790A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026050446A1 (fr) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026072904A2 (fr) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions et méthodes de traitement du cancer du poumon |
| WO2026090116A2 (fr) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (fr) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Utilisation d'inhibiteurs ras pour traiter un cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999002557A1 (fr) | 1997-07-11 | 1999-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V | Nouveaux composes pharmaceutiquement actifs entrant en interaction avec des proteines de liaison de gtp |
| KR20110033223A (ko) | 2008-06-20 | 2011-03-30 | 제넨테크, 인크. | 트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법 |
| CN104379563B (zh) | 2012-04-10 | 2018-12-21 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| JP6559123B2 (ja) * | 2013-10-10 | 2019-08-14 | アラクセス ファーマ エルエルシー | Ｋｒａｓｇ１２ｃの阻害剤 |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| WO2016049568A1 (fr) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Méthodes et compositions permettant l'inhibition de la ras |
| MX382355B (es) | 2015-04-10 | 2025-03-13 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos. |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017070256A2 (fr) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Méthode de criblage d'inhibiteurs de ras |
| EP3377481A1 (fr) | 2015-11-16 | 2018-09-26 | Araxes Pharma LLC | Composés quinazoline substitués en position 2 comprenant un groupe hétérocyclique substitué et leur méthode d'utilisation |
| WO2017100546A1 (fr) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Procédés de préparation de dérivés de quinazoléine |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| CN109843856B (zh) | 2016-05-18 | 2023-05-02 | 米拉蒂治疗股份有限公司 | Kras g12c抑制剂 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| CN110831933A (zh) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | 喹唑啉衍生物作为突变kras、hras或nras的调节剂 |
| CN110869358A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
| JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
| KR102861303B1 (ko) | 2017-11-15 | 2025-09-17 | 미라티 테라퓨틱스, 인크. | Ｋｒａｓ ｇ12ｃ 억제제 |
| CA3086172A1 (fr) | 2017-12-19 | 2019-06-27 | Merck Patent Gmbh | Antagonistes de tlr7/8 et leurs utilisations |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
-
2019
- 2019-11-08 ES ES19842848T patent/ES3004042T3/es active Active
- 2019-11-08 LT LTEPPCT/US2019/060578T patent/LT3735299T/lt unknown
- 2019-11-08 FI FIEP19842848.4T patent/FI3735299T3/fi active
- 2019-11-08 TW TW111140273A patent/TWI883352B/zh active
- 2019-11-08 PL PL19842848.4T patent/PL3735299T3/pl unknown
- 2019-11-08 BR BR112021008986-1A patent/BR112021008986A2/pt unknown
- 2019-11-08 SI SI201930862T patent/SI3735299T1/sl unknown
- 2019-11-08 EP EP24198360.0A patent/EP4483881A3/fr active Pending
- 2019-11-08 WO PCT/US2019/060578 patent/WO2020097537A2/fr not_active Ceased
- 2019-11-08 TW TW108140719A patent/TWI784209B/zh active
- 2019-11-08 AU AU2019377130A patent/AU2019377130B2/en active Active
- 2019-11-08 PT PT198428484T patent/PT3735299T/pt unknown
- 2019-11-08 CN CN202410280943.8A patent/CN118084867A/zh active Pending
- 2019-11-08 AR ARP190103302A patent/AR117194A1/es unknown
- 2019-11-08 CN CN202410280860.9A patent/CN118084866A/zh active Pending
- 2019-11-08 US US16/679,104 patent/US11236068B2/en active Active
- 2019-11-08 CN CN202410281087.8A patent/CN118084870A/zh active Pending
- 2019-11-08 KR KR1020207024122A patent/KR102587544B1/ko active Active
- 2019-11-08 HU HUE19842848A patent/HUE069365T2/hu unknown
- 2019-11-08 SM SM20240487T patent/SMT202400487T1/it unknown
- 2019-11-08 IL IL311187A patent/IL311187B2/en unknown
- 2019-11-08 CA CA3087089A patent/CA3087089C/fr active Active
- 2019-11-08 SG SG11202103298QA patent/SG11202103298QA/en unknown
- 2019-11-08 MX MX2021005428A patent/MX2021005428A/es unknown
- 2019-11-08 KR KR1020257000144A patent/KR20250012188A/ko active Pending
- 2019-11-08 PE PE2025003077A patent/PE20260440A1/es unknown
- 2019-11-08 JP JP2020542808A patent/JP6941241B2/ja active Active
- 2019-11-08 RS RS20241331A patent/RS66280B1/sr unknown
- 2019-11-08 MY MYPI2021002582A patent/MY196726A/en unknown
- 2019-11-08 IL IL282916A patent/IL282916B2/en unknown
- 2019-11-08 HR HRP20241581TT patent/HRP20241581T1/hr unknown
- 2019-11-08 CN CN202410281112.2A patent/CN118084868A/zh active Pending
- 2019-11-08 CR CR20210229A patent/CR20210229A/es unknown
- 2019-11-08 DK DK19842848.4T patent/DK3735299T3/da active
- 2019-11-08 KR KR1020237033977A patent/KR102751492B1/ko active Active
- 2019-11-08 EP EP19842848.4A patent/EP3735299B1/fr active Active
- 2019-11-08 UA UAA202101478A patent/UA127930C2/uk unknown
- 2019-11-08 MA MA51530A patent/MA51530B1/fr unknown
- 2019-11-08 PE PE2021000682A patent/PE20211504A1/es unknown
- 2019-11-08 CN CN201980026181.6A patent/CN112105419B/zh active Active
-
2021
- 2021-05-04 CL CL2021001171A patent/CL2021001171A1/es unknown
- 2021-05-07 MX MX2025002979A patent/MX2025002979A/es unknown
- 2021-05-07 MX MX2024008118A patent/MX2024008118A/es unknown
- 2021-05-07 CO CONC2021/0005987A patent/CO2021005987A2/es unknown
- 2021-05-07 MX MX2025002975A patent/MX2025002975A/es unknown
- 2021-05-07 MX MX2025002980A patent/MX2025002980A/es unknown
- 2021-05-07 PH PH12021551065A patent/PH12021551065A1/en unknown
- 2021-07-15 JP JP2021116809A patent/JP7374960B2/ja active Active
- 2021-12-17 US US17/644,993 patent/US12084429B2/en active Active
-
2022
- 2022-03-01 AU AU2022201413A patent/AU2022201413B9/en active Active
- 2022-03-22 CL CL2022000698A patent/CL2022000698A1/es unknown
-
2023
- 2023-10-25 JP JP2023183500A patent/JP7579414B2/ja active Active
-
2024
- 2024-02-13 AU AU2024200904A patent/AU2024200904B2/en active Active
- 2024-06-18 US US18/747,054 patent/US20250059163A1/en active Pending
- 2024-10-25 JP JP2024187827A patent/JP2025026853A/ja active Pending
-
2025
- 2025-10-20 IL IL324078A patent/IL324078A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551065A1 (en) | Fused ring compounds | |
| MA64509B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA45020A (fr) | Dérivés sulfonamides aromatiques | |
| MA64121B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| EA202092899A1 (ru) | Гетероарильные соединения для лечения болезни гентингтона | |
| MA41562A1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA38483A1 (fr) | Inhibiteurs de l'ido | |
| MA39721A (fr) | Nouvelles héteroaryldihydropyrimidines condensées en position 6 pour le traitement et la prophylaxie d'une infection à virus de l'hépatite b | |
| MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
| MA54386B1 (fr) | Modulateurs de trex1 | |
| MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA40378A (fr) | Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de tétrahydroquinoléine | |
| MA50406B1 (fr) | Inhibiteurs pyrazole de magl | |
| MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| MA46342A (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
| MA39337A1 (fr) | Modulateurs de pyrazines de gpr6 | |
| SA522441650B1 (ar) | مثبطات فوسفوينوسيتيد 3-كيناز الموضعية | |
| MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
| FR3078704B1 (fr) | Derives d'isohexide et leurs utilisations | |
| EA202191477A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| MA52375B2 (fr) | Inhibiteurs de cdk8/19 | |
| MA45392B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA43507B1 (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue |